Tenet Healthcare is a Dallas-based healthcare services organization. It operates acute and specialty hospitals (50 as of December 2025) and hundreds of ambulatory surgery centers and other outpatient facilities across the US, primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
HCA Healthcare, Inc.
Acadia Healthcare Company, Inc.
Community Health Systems, Inc.
Encompass Health Corporation Common Stock
SELECT MEDICAL HOLDINGS CORP
Universal Health Services, Inc. Class B
Surgery Partners, Inc. Common Stock
The chart shows the growth of an initial investment of $10,000 in Tenet Healthcare Corporation New, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Tenet Healthcare Corporation New (THC) has returned -5.38% so far this year and 61.39% over the past 12 months. Looking at the last ten years, THC has achieved an annualized return of 20.61%, outperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of Tenet Healthcare Corporation New (THC) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.82% | 26.17% | -20.38% | -0.78% | ||||||||
| 2025 | 10.61% | -8.53% | 5.33% | 5.41% | 17.81% | 4.06% | -8.37% | 14.68% | 10.60% | 2.10% | 5.37% | -7.88% |
| 2024 | 10.04% | 9.37% | 12.54% | 7.09% | 19.85% | -1.30% | 11.65% | 10.29% | 0.56% | -6.24% | -8.88% | -11.26% |
| 2023 | 11.35% | 7.61% | 2.24% | 23.52% | -2.71% | 14.62% | -7.55% | 1.25% | -15.45% | -18.44% | 29.43% | 9.65% |
| 2022 | -9.28% | 15.73% | 0.22% | -16.38% | -10.76% | -19.85% | 27.33% | -13.62% | -7.70% | -15.31% | 2.74% | 4.30% |
| 2021 | 17.21% | 6.29% | 1.13% | 13.83% | 10.12% | -0.43% | 6.47% | 4.49% | -12.20% | 7.13% | 1.77% | 9.59% |
| 2020 | -17.17% | -17.54% | -45.89% | 49.81% | 13.57% | -17.72% | 46.48% | 6.22% | -12.24% | 0.20% | 24.62% | 23.81% |
| 2019 | 30.35% | 30.62% | -0.14% | -24.48% | -8.15% | 3.61% | 12.72% | -7.87% | 4.09% | 13.79% | 25.49% | 17.30% |
| 2018 | 23.80% | 9.75% | 16.87% | -0.91% | 41.16% | -5.52% | 12.77% | -10.27% | -15.50% | -10.19% | 0.70% | -35.39% |
| 2017 | 17.42% | 9.41% | -7.76% | -11.77% | 6.16% | 16.23% | -10.66% | -1.89% | -6.17% | -13.30% | 0.07% | 7.98% |
| 2016 | 10.07% | -8.68% | -3.83% | 10.67% | -21.82% | -5.54% | -12.13% | -26.25% | -2.56% |
The charts below present risk-adjusted performance metrics for Tenet Healthcare Corporation New (THC) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of THC compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current Tenet Healthcare Corporation New volatility is 1.78%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 29.68B | 28.94B | 28.94B | 28.31B | 27.16B | 27.58B | 27.11B | 23.35B | 22.41B | 23.39B | 24.70B | 23.68B | 18.14B | 16.13B | 9.04B |
| Temporary Equity (USD) | 2.96B | 2.73B | 2.73B | 2.39B | 2.15B | 2.20B | 1.95B | 1.51B | 1.42B | 1.87B | 2.39B | 2.27B | 401.00M | 247.00M | 16.00M |
| Equity Attributable To Parent (USD) | 4.22B | 4.17B | 4.17B | 1.61B | 1.14B | 1.03B | 28.00M | -371.00M | -119.00M | -147.00M | 417.00M | 691.00M | 651.00M | 755.00M | 1.14B |
| Equity Attributable To Noncontrolling Interest (USD) | 1.80B | 1.65B | 1.65B | 1.51B | 1.32B | 1.03B | 909.00M | 854.00M | 806.00M | 686.00M | 665.00M | 267.00M | 134.00M | 123.00M | 75.00M |
| Equity (USD) | 6.02B | 5.82B | 5.82B | 3.12B | 2.46B | 2.05B | 937.00M | 483.00M | 687.00M | 539.00M | 1.08B | 958.00M | 785.00M | 878.00M | 1.22B |
| Redeemable Noncontrolling Interest (USD) | 2.96B | 2.73B | 2.73B | 2.39B | 2.15B | 2.20B | 1.95B | 1.51B | 1.42B | 1.87B | 2.39B | 2.27B | 401.00M | 247.00M | 16.00M |
| Noncurrent Liabilities (USD) | 16.24B | 16.08B | 16.08B | 18.04B | 18.07B | 18.21B | 19.37B | 17.16B | 16.45B | 16.65B | 17.19B | 16.15B | 13.38B | 12.08B | 6.05B |
| Other Current Liabilities (USD) | 2.25B | 2.12B | 2.12B | 2.42B | 2.19B | 2.91B | 2.70B | 2.12B | 1.81B | 2.31B | 1.83B | 2.05B | 1.55B | 1.22B | 626.00M |
| Wages (USD) | 858.00M | 899.00M | 899.00M | 930.00M | 778.00M | 896.00M | 942.00M | 877.00M | 838.00M | 848.00M | 872.00M | 880.00M | 852.00M | 631.00M | 415.00M |
| Accounts Payable (USD) | 1.36B | 1.29B | 1.29B | 1.41B | 1.50B | 1.30B | 1.21B | 1.20B | 1.21B | 1.18B | 1.33B | 1.38B | 1.18B | 1.08B | 722.00M |
| Current Liabilities (USD) | 4.46B | 4.31B | 4.31B | 4.76B | 4.48B | 5.11B | 4.85B | 4.21B | 3.86B | 4.33B | 4.03B | 4.31B | 3.58B | 2.93B | 1.76B |
| Liabilities (USD) | 20.70B | 20.39B | 20.39B | 22.80B | 22.55B | 23.32B | 24.22B | 21.36B | 20.30B | 20.98B | 21.23B | 20.46B | 16.96B | 15.01B | 7.81B |
| Other Non-current Assets (USD) | 17.60B | 16.82B | 16.82B | 16.62B | 16.60B | 15.75B | 15.83B | 14.30B | 7.59B | 7.47B | 8.30B | 7.75B | 4.03B | 4.32B | 1.91B |
| Intangible Assets (USD) | 1.35B | 1.40B | 1.40B | 1.37B | 1.42B | 1.50B | 1.60B | 1.60B | 1.73B | 1.77B | 1.85B | 1.68B | 1.28B | - | - |
| Fixed Assets (USD) | - | - | - | - | - | - | - | - | 6.99B | 7.03B | 8.05B | 7.92B | 7.73B | 7.69B | 4.29B |
| Long Term Investments (USD) | 2.88B | 3.04B | 3.04B | 3.16B | 3.15B | 3.25B | 2.53B | 2.37B | 1.46B | 1.54B | 1.25B | 1.18B | 384.00M | 405.00M | 162.00M |
| Noncurrent Assets (USD) | 21.83B | 21.25B | 21.25B | 21.15B | 21.18B | 20.50B | 19.96B | 18.27B | 17.77B | 17.81B | 19.44B | 18.51B | 13.42B | 12.42B | 6.36B |
| Other Current Assets (USD) | 7.08B | 6.97B | 6.97B | 6.37B | 5.18B | 6.69B | 6.78B | 4.77B | 4.33B | 5.28B | 4.93B | 4.86B | 4.44B | 3.45B | 2.45B |
| Prepaid Expenses (USD) | 423.00M | 368.00M | 368.00M | 391.00M | 400.00M | - | - | - | - | - | - | - | - | - | 76.00M |
| Inventory (USD) | 348.00M | 346.00M | 346.00M | 411.00M | 405.00M | 384.00M | 368.00M | 310.00M | 305.00M | 289.00M | 326.00M | 309.00M | 276.00M | 262.00M | 153.00M |
| Current Assets (USD) | 7.85B | 7.68B | 7.68B | 7.17B | 5.98B | 7.08B | 7.15B | 5.08B | 4.64B | 5.57B | 5.26B | 5.17B | 4.72B | 3.71B | 2.68B |
| Assets (USD) | 29.68B | 28.94B | 28.94B | 28.31B | 27.16B | 27.58B | 27.11B | 23.35B | 22.41B | 23.39B | 24.70B | 23.68B | 18.14B | 16.13B | 9.04B |
Tenet Healthcare reported strong Q4 2025 results with sales of $5.527 billion (up 8.9% YoY) and adjusted EPS of $4.70 (up from $3.44), beating consensus estimates. The company saw growth across both hospital operations and ambulatory segments, driven by higher acuity cases and favorable payer mix. For 2026, Tenet expects revenue guidance of $21.5-$22.3 billion and adjusted EBITDA of $4.485-$4.785 billion, with shares rising 6.73% on the news.
Tenet Healthcare demonstrates strong financial performance with impressive Q2 2025 results, featuring revenue growth, margin expansion, and strategic focus on ambulatory care. The company shows potential for growth despite potential future Medicaid policy challenges.
Tenet Healthcare reported strong Q2 2025 earnings, with adjusted EPS of $4.02, exceeding analyst expectations. The company saw revenue growth in Ambulatory Care and raised its full-year financial guidance, driven by margin improvements and strategic portfolio shifts.
Several large-cap companies, including Duolingo, CoreWeave, and DexCom, saw significant gains last week due to strong earnings, sales guidance, and analyst upgrades.
The global plastic fencing market is expected to grow significantly due to rising demand from the residential and commercial construction industries, as well as the increasing adoption of recycled plastics in fencing products.
Tenax Therapeutics, a Phase 3 pharmaceutical company, announced its participation in the Guggenheim SMID Cap Biotech Conference, where its President and CEO will present in a fireside chat.
The White House has ordered a temporary freeze on all federal grants and loans, putting $3 trillion in funding under scrutiny and threatening industries like clean energy, defense, and healthcare.
The behavioral rehabilitation market is expected to grow rapidly, driven by increasing mental health awareness and the rising global addiction crisis. The substance abuse disorder segment dominates the market, with a focus on personalized treatments and innovations in telemedicine. North America leads the market due to high awareness of dementia and a strong healthcare system.
The Ensign Group has acquired the operations of a nursing facility in Kansas and seven nursing facilities in Colorado, expanding its footprint in these states. The acquisitions are expected to increase the company's revenues and profits.
The Europe pavement reinforcement materials market is expected to grow at a CAGR of 8.3% from 2024 to 2030, driven by increasing urbanization, smart city initiatives, and the shift towards alternative transportation modes. Key materials include carbon fiber, glass fiber, and steel rebar.